This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Diamandi, A. Articles by Khosravi, J. Search for Related Content PubMed PubMed Citation Articles by Diamandi, A. Articles by Khosravi, J.

Immunoassay of Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3): New Means to Quantifying IGFBP-3 Proteolysis

Diagnostics Systems Laboratories, Inc. (Canada) (A.D., J.K.), Toronto, Ontario, Canada M5G 1X5; Diagnostics Systems Laboratories, Inc. (J.M., R.G.K.), Webster, Texas 77598; and Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto (J.K.), Toronto, Ontario, Canada M5G 1L5

Address all correspondence and requests for reprints to: J. Khosravi, Ph.D., Diagnostics Systems Laboratories, Inc. (Canada), Mount Sinai Hospital, Room 653, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5. E-mail: jkhosravi{at}mtsinai.on.ca

Posttranslational modifications, particularly proteolysis, may play a significant role in the regulation of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) physiology, and thus, measurement of modified variants of IGFBP-3 and/or their combination ratios may have important research and diagnostic relevance. Based on evaluation of a panel of monoclonal and polyclonal IGFBP-3 antibodies, we constructed three new enzyme-linked immunosorbent assays (ELISAs) using a common capture and polyclonal (ELISA-3) or monoclonal (ELISA-1 and -2) detection antibodies and evaluated them in a two-step colorimetric procedure. Evaluation of ELISA-1–3 demonstrated detection limit, dynamic range, overall precision, and recovery of the added IGFBP-3 to be generally less than 0.04 µg/L, 2–100 µg/L, less than 10%, and 91–113%, respectively. IGF-I and -II, and IGFBP-1, -2, -4, -5, and -6 did not interfere. In normal adult sera (n = 26), seminal plasma (n = 14), pregnancy sera (n = 30), and amniotic fluid (n = 30), ELISA-1–3 detected significantly different IGFBP-3 levels (by up to 6-fold, on the average), whereas levels in seminal plasma determined by ELISA-1 were undetectable. Comparison of the values obtained vs. corresponding levels by an established method (Diagnostic Systems Laboratories, Inc., active IGFBP-3 ELISA) were similarly sample dependent and, on the average, varied by up to 19-fold. Only ELISA-3 compared well with the Diagnostic Systems Laboratories, Inc., IGFBP-3 ELISA when samples from normal adults were analyzed. The observed variability could not be totally explained by 50% lower reactivity of ELISA-1–3 for glycosylated IGFBP-3 vs. the nonglycosylated form, and changes in phosphorylation had no effect on immunoreactivity. Evaluation of IGFBP-3 after proteolysis by seminal plasma, plasmin, or thrombin suggested recognition of intact IGFBP-3 by ELISA-1, whereas ELISA-3 appeared to measure intact and proteolyzed IGFBP-3 (total IGFBP-3) with similar potency. In contrast, levels determined by ELISA-2 increased severalfold, indicating preferential recognition of IGFBP-3 fragments. We propose that immunoassay capable of differential determination of IGFBP-3 variants may help better define the physiological importance and potential clinical value of IGFBP-3 measurements.

This article has been cited by other articles:

				D. K. Tisi, X.-J. Liu, L. J. Wykes, C. D. Skinner, and K. G. Koski Insulin-Like Growth Factor II and Binding Proteins 1 and 3 from Second Trimester Human Amniotic Fluid Are Associated with Infant Birth Weight J. Nutr., July 1, 2005; 135(7): 1667 - 1672. [Abstract] [Full Text] [PDF]

				S. Rinaldi, R. Kaaks, A. Zeleniuch-Jacquotte, A. A. Arslan, R. E. Shore, K. L. Koenig, L. Dossus, E. Riboli, P. Stattin, A. Lukanova, et al. Insulin-Like Growth Factor-I, IGF Binding Protein-3, and Breast Cancer in Young Women: A Comparison of Risk Estimates Using Different Peptide Assays Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 48 - 52. [Abstract] [Full Text] [PDF]

				R. Coutant, F. Boux de Casson, O. Douay, E. Mathieu, S. Rouleau, F. Beringue, P. Gillard, J. M. Limal, and P. Descamps Relationships between Placental GH Concentration and Maternal Smoking, Newborn Gender, and Maternal Leptin: Possible Implications for Birth Weight J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4854 - 4859. [Abstract] [Full Text] [PDF]

				M. Binoux Tools Now Exist to Measure Circulating IGF-Binding Protein-3 Proteolysis, to Study Its Regulation and Its Effects on IGF-I Bioavailability J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 5088 - 5089. [Full Text] [PDF]

				J. Khosravi, A. Diamandi, J. Mistry, and A. Scorilas Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Benign Prostatic Hyperplasia and Prostate Cancer J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 694 - 699. [Abstract] [Full Text]